Aimmune Therapeutics (Aimmune Therapeutics) Effective Interest Rate on Debt % : 9.06% (As of Jun. 2020)

View and export this data going back to 2015. Start your Free Trial

What is Aimmune Therapeutics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Aimmune Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Jun. 2020 was $12.85 Mil. Aimmune Therapeutics's average total debt for the quarter that ended in Jun. 2020 was $141.79 Mil. Therefore, Aimmune Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2020 was 9.06%.

Aimmune Therapeutics Effective Interest Rate on Debt % Historical Data

The historical data trend for Aimmune Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aimmune Therapeutics Effective Interest Rate on Debt % Chart

Aimmune Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

9.14

Aimmune Therapeutics Quarterly Data
	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															9.85	-	36.79	9.18	9.06

Competitive Comparison of Aimmune Therapeutics's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Aimmune Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aimmune Therapeutics's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aimmune Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Aimmune Therapeutics's Effective Interest Rate on Debt % falls into.

Aimmune Therapeutics Effective Interest Rate on Debt % Calculation

Aimmune Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2019 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2018 )	+	Total Debt (A: Dec. 2019 ))	/ count )
=	-1 * -4.916	/	( (0	+	53.809)	/ 1 )
=	-1 * -4.916	/	53.809
=	9.14 %

where

	Total Debt (A: Dec. 2018 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	0
=	0

	Total Debt (A: Dec. 2019 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	51.552	+	2.257
=	53.809

Aimmune Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2020 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Mar. 2020 )	+	Total Debt (Q: Jun. 2020 ))	/ count )
=	-1 * -12.848	/	( (140.389	+	143.184)	/ 2 )
=	-1 * -12.848	/	141.7865
=	9.06 %

where

	Total Debt (Q: Mar. 2020 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	138.074	+	2.315
=	140.389

	Total Debt (Q: Jun. 2020 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	140.785	+	2.399
=	143.184

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Jun. 2020) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Aimmune Therapeutics (NAS:AIMT) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Aimmune Therapeutics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Aimmune Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aimmune Therapeutics (Aimmune Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aimmune Therapeutics Inc (NAS:AIMT) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

N/A

Address

8000 Marina Boulevard, Suite 300, Brisbane, CA, USA, 94005

Website

https://www.aimmune.com

Aimmune Therapeutics Inc is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.

Executives

Gregory Behar	director	C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Societe Des Produits Nestle S.a.	10 percent owner	AVENUE NESTLE 55, VEVEY V8 CH-1800
Kathryn E Falberg	director	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Andrew Oxtoby	officer: Chief Commercial Officer	8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Dallas Jayson Donald Alexander	director, officer: President and CEO	AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005
Stacey Denenberg Seltzer	director	C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Brett K Haumann	director	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Douglas T. Sheehy	officer: See Remarks	C/O AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE CA 94005-1884
Mark T Iwicki	director	84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Patrick G Enright	director	CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Mark Mcdade	director	C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Adelman Daniel C Md	officer: Chief Medical Officer	23 WOODLEAF AVENUE, REDWOOD CITY CA 94061
Eric Bjerkholt	officer: Chief Financial Officer	132 PURDURE AVENUE, KENGSINGTON CA 94708
Sa Nestle	10 percent owner	AVE NESTLE 55, CH-1800, VEVEY V8
Mary M. Rozenman	officer: See Remarks	AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300 BRISBANE CA 94005